The global dengue testing market was valued at USD 612.53 million in 2024 and is projected to grow steadily, reaching USD 822.61 million by 2030. This expansion reflects a compound annual growth rate (CAGR) of 5.22% from 2025 to 2030. The market growth is being strongly driven by several interlinked factors, including the increasing frequency of dengue outbreaks, rapid advancements in diagnostic technologies, and expanding public health initiatives worldwide.

The urgency for improved testing solutions was highlighted by the 2024 dengue epidemic in Latin America and the Caribbean, which recorded over 13 million suspected cases and more than 8,000 deaths. This crisis not only exposed gaps in existing healthcare infrastructure but also emphasized the critical importance of timely and reliable diagnostics to support outbreak management and reduce mortality rates.

The dengue testing industry is undergoing significant technological transformation, particularly in the areas of rapid diagnostic solutions and molecular assays. Several innovations are reshaping the competitive landscape:

• RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) continues to set the standard for accuracy and sensitivity in detecting dengue virus RNA, playing a vital role in confirmatory testing.
• CRISPR-based diagnostic assays are emerging as a breakthrough, offering rapid, highly specific, and cost-efficient detection methods, especially valuable in outbreak-prone regions.
• Home-based NS1 antigen test kits are making diagnostics more accessible, enabling early detection and faster isolation, which is crucial for preventing community spread.
• Multiplex assays, developed by startups and research institutions, are gaining traction. These advanced tests can differentiate dengue from other arboviral infections such as Zika and chikungunya, which often present with similar symptoms. The ability to distinguish between these infections is becoming a key competitive advantage for test developers and manufacturers.

Overall, innovation remains the cornerstone of the dengue testing market, as companies and institutions strive to improve diagnostic speed, affordability, and accessibility.

Key Market Trends & Insights:

• Asia Pacific emerged as the dominant regional market in 2024, contributing the largest revenue share of 31.57%. This leadership is attributed to high dengue prevalence, strong government-led awareness programs, and expanding healthcare infrastructure. Within the region, Japan is witnessing notable growth due to government-funded surveillance initiatives and the broader adoption of RT-PCR and automated ELISA technologies in public health laboratories. These measures have strengthened the country’s diagnostic capacity and preparedness against dengue outbreaks.
• ELISA-based tests accounted for the largest market share at 44.94% in 2024, as they remain the gold standard for laboratory-based dengue diagnosis due to their high sensitivity and reliability. The lateral flow immunoassay (LFIA) segment is projected to record the fastest CAGR during the forecast period, supported by its ease of use, portability, and suitability for point-of-care (POC) testing in resource-limited settings.
• Centralized testing services led the market in 2024, holding a 59.93% share, owing to their established infrastructure, specialized equipment, and ability to process large sample volumes efficiently. However, the point-of-care (POC) service segment is expected to expand at the fastest growth rate, driven by increasing demand for rapid, field-deployable testing solutions in outbreak-hit areas.
• Clinical laboratories dominated the market with a 44.16% revenue share in 2024, reflecting their role as primary testing centers for both routine and outbreak-driven dengue diagnostics. The government suppliers segment is projected to witness the fastest growth over the forecast period, as national health agencies increasingly procure large-scale diagnostic solutions for mass screening and epidemic control initiatives.

Order a free sample PDF of the Dengue Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 612.53 Million
• 2030 Projected Market Size: USD 822.61 Million
• CAGR (2025-2030): 5.22%
• Asia Pacific: Largest market in 2024

Key Players

The following are the leading companies in the dengue testing market. These companies collectively hold the largest market share and dictate industry trends.

• Thermo Fisher Scientific Inc.
• Abbott
• F. Hoffmann‑La Roche Ltd.
• InBios International, Inc.
• NovaTec Immundiagnostica GmbH
• Abnova Corporation
• PerkinElmer Inc. (Euroimmun AG)
• Certest Biotec
• DiaSorin S.p.A.
• Quest Diagnostics Incorporated

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global dengue testing market is witnessing steady growth, supported by the rising global disease burden, technological innovations, and government-led health programs. Asia Pacific continues to play a pivotal role, while new diagnostic platforms such as CRISPR-based assays and multiplex tests are expected to redefine competitive dynamics. With the ongoing threat of severe dengue outbreaks, the demand for faster, more accurate, and widely accessible diagnostic solutions will remain at the forefront of market expansion.